07:00 , Sep 12, 2011 |  BioCentury  |  Finance

Playing chess

Playing chess Massachusetts-based GI Dynamics Inc. (ASX:GID) opted to price its IPO on the Australian Securities Exchange on the advice of board members with experience listing U.S. life sciences companies on the ASX. A driver...
07:00 , Aug 8, 2011 |  BioCentury  |  Finance

Playing CHESS

Playing CHESS U.S. obesity play GI Dynamics Inc. hopes to gain three years of runway in an Australian IPO to commercialize its EndoBarrier Gastrointestinal Liner to treat obesity and Type II diabetes. EndoBarrier is intended...
07:00 , Apr 18, 2001 |  BC Extra  |  Financial News

Novazyme raises $16 million

Novazyme Pharmaceuticals (Oklahoma City, Okla.) raised $16 million in a private financing. Investors included Perseus-Soros Biopharmaceutical Fund; HealthCare Ventures; Catalyst Health & Technology Partners; and Morgan Stanley Dean Witter Equity Funding. Novazyme is developing therapeutics...
07:00 , Sep 19, 2000 |  BC Extra  |  Financial News

Novazyme raises $8 million

Novazyme (Oklahoma City, Okla.), which is developing treatments for lysosomal storage disorders, raised $8 million in a private round. Investors included Catalyst Health & Technology Partners; HealthCare Ventures; and Perseus-Soros Biopharmaceutical Fund....